GET DAILY SIGNALSBaxter International (BAX) Delivers Q3 Revenue of $2.98 Billion, Up +5%, and Raises Full-Year Guidance
Key Takeaways
- Baxter International reported Q3 2026 revenue of $2.98 billion, up 5% year over year and above the roughly $2.91 billion Wall Street consensus estimate.
- Adjusted earnings per share (EPS) came in at $0.58, topping the $0.52 consensus and beating expectations by about 12%.
- On a GAAP (Generally Accepted Accounting Principles) basis, the company swung to net income of $294 million from a net loss of $46 million a year earlier.
- Management raised its full-year 2026 outlook, lifting organic sales growth guidance to 3%–4% and adjusted EPS guidance to $2.05–$2.15.
- Free cash flow improved sharply, reaching $448 million in the quarter and $705 million year to date, supporting the company's debt-reduction goals.
Why This Quarter Matters for the Turnaround Story
Baxter International’s third-quarter results carry extra significance because they provide a clear snapshot of the medical technology company’s ongoing multi-year turnaround. After divesting its Kidney Care business, Baxter has focused on stabilizing operations, improving its balance sheet, and rebuilding consistent organic growth. Earlier periods had shown mixed progress, with margin pressure and supply-chain issues offsetting solid underlying demand. This report served as an important check on whether restructuring efforts are producing lasting results. For investors, the implications go beyond one quarter—progress on debt reduction, free cash flow, and updated guidance indicates whether Baxter can regain credibility in its infusion, advanced surgery, and connected-care markets.
Breaking Down the Reported Results
Baxter posted third-quarter 2026 revenue of $2.98 billion, a 5% increase on both a reported and organic basis from $2.835 billion a year earlier. The top line came in ahead of the approximately $2.91 billion consensus estimate. Adjusted diluted EPS reached $0.58, surpassing the $0.52 consensus, though it fell 16% year over year from $0.69; management linked the decline to a higher effective tax rate after the prior-year quarter benefited from discrete tax items. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On a GAAP basis, Baxter reported net income of $294 million, reversing a net loss of $46 million in the prior-year quarter, with diluted EPS of $0.57. Adjusted operating income totaled $432 million, reflecting a 14.5% margin and exceeding the roughly $403 million consensus. By segment, Medical Products & Therapies sales rose 6% organically to about $2.1 billion, while Healthcare Systems & Technologies sales grew 4% to $806 million. Free cash flow reached $448 million for the quarter and $705 million year to date.
Management raised its full-year 2026 guidance, increasing organic sales growth expectations to 3%–4% from 2%–3% and adjusted EPS guidance to $2.05–$2.15 from $1.95–$2.15.
How the Market Reacted to the Print
Shares of BAX rose roughly 3.4% to about $26.34 right after the report, showing investor approval of the revenue and EPS beats along with the raised full-year guidance. Sentiment before the release had been cautious, with analysts monitoring whether cost pressures and supply-chain challenges would again limit profitability. The beats on both top and bottom lines, together with stronger free cash flow, helped ease some of those concerns.
Even so, the reaction stayed measured rather than exuberant. Investors continue to watch margin headwinds, pricing dynamics in injectables, and ongoing restructuring costs. The stock’s subsequent trading reflected a market balancing near-term execution gains against the longer path still ahead for leverage reduction and steady margin expansion.
What to Watch in the Outlook Ahead
Baxter enters the fourth quarter with raised full-year guidance, projecting organic sales growth of 3%–4% and adjusted EPS of $2.05–$2.15. Management expects fourth-quarter organic sales growth of around 5%, with operating margin remaining near third-quarter levels.
Investors should keep an eye on several factors. First, the company is discontinuing production of cephalosporin products at its Round Lake facility, an action expected to contribute roughly $50 million in sales and $30 million in operating income in 2026 but which carries restructuring costs and operational simplification benefits into 2027. Second, balance-sheet progress stays central, with management targeting a net leverage ratio of approximately 3.0x by year-end.
Third, watch demand signals in Infusion Therapies & Platforms, Drug Compounding, and Advanced Surgery, which have been key growth drivers. Hospital capital spending trends, inflation, and interest-rate pressures could also influence the Healthcare Systems & Technologies segment. Finally, tariff impacts—estimated at around $80 million in guidance assumptions—and foreign exchange movements may affect reported results. These elements will determine whether Baxter’s turnaround maintains momentum through 2027.
AI Tools That Support My Research Process
From what I see, Tickeron’s AI Screener offers a practical way to scan healthcare names and compare technical patterns, fundamentals, and performance metrics side by side. I find it helpful for surfacing ideas and monitoring sector conditions without spending excessive time on manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BAX in downward trend: price dove below 50-day moving average on October 29, 2026
BAX moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend. In 24 of 32 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 75%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BAX moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 21 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 55 cases where BAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAX as a result. In 62 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for BAX turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 34 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
Bullish Trend Analysis
The 10-day moving average for BAX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +4.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 166 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
BAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 143 of 210 cases where BAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.958) is normal, around the industry mean (5.000). P/E Ratio (-11.353) is within average values for comparable stocks, (37.535). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (4.143). Dividend Yield (0.002) settles around the average of (0.005) among similar stocks. P/S Ratio (1.057) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices
Industry PharmaceuticalsOther
Advertisement